

What is claimed is:

1. A method of treating a patient having an amyloid deposition disease comprising the step of administering to the patient
 - 5 a) a therapeutically effective dose of at least one immunoglobulin polypeptide or a fragments thereof, wherein the immunoglobulin polypeptide or fragment thereof binds to an amyloid fibril; and
 - b) a pharmaceutically acceptable carrier.
- 10 *bind* 2. The method of claim 1, wherein the immunoglobulin polypeptide or fragment thereof is raised against an immunoglobulin light-chain.
- fibril* 3. The method of claim 1, wherein binding of the immunoglobulin polypeptide or fragment thereof opsonizes the amyloid fibril.
- 15 4. The method of claim 1, wherein the immunoglobulin polypeptide or fragment thereof is a monoclonal antibody.
- 20 5. The method of claim 4, wherein the monoclonal antibody is a humanized antibody.
6. The method of claim 4, wherein the monoclonal antibody is a chimeric antibody.
- 25 7. The method of claim 6, wherein the chimeric antibody is a humanized antibody.
8. The method of claim 4, wherein the antibody is a labeled antibody.
9. The method of claim 4, wherein the monoclonal antibody is selected from the group consisting of $\kappa 1$ (57-18H12), $\kappa 4$ (11-1F4), $\lambda 8$ (31-8C7), and combinations thereof.
- 30

shy

10. An immunoglobulin polypeptide or fragment thereof that binds to an amyloid fibril and is effective to enhance the cellular immune response of a patient to remove disease-associated amyloid fibril deposits.

5 11. The immunoglobulin polypeptide or fragment thereof of claim 10, wherein the immunoglobulin polypeptide or fragment thereof is a monoclonal antibody or fragment thereof.

10 12. The immunoglobulin or fragment thereof of claim 11, wherein the monoclonal antibody is a humanized antibody.

13. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the monoclonal antibody is a chimeric antibody.

15 14. The immunoglobulin polypeptide or fragment thereof of claim 13, wherein the chimeric antibody is a humanized antibody.

15 15. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the antibody is a labeled antibody.

20 16. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the monoclonal antibody is selected from the group consisting of $\kappa 1$ (57-18H12), $\kappa 4$ (11-1F4), $\lambda 8$ (31-8C7), and combinations thereof.

25 17. The monoclonal antibody or fragment thereof of claim 16, wherein the monoclonal antibody is a humanized antibody.

30 18. The immunoglobulin polypeptide or fragment thereof of claim 10, wherein the immunoglobulin polypeptide or fragment thereof has been raised against synthetic amyloid fibrils.

19. A pharmaceutical composition comprising the immunoglobulin peptide or fragment thereof of claim 10.

5 20. A nucleic acid molecule which encodes a polypeptide comprising at least a hypervariable region of the immunoglobulin polypeptide of claim 10.

21. A host cell comprising a nucleic acid molecule of claim 20.

10 22. A method of producing an immunoglobulin polypeptide comprising the step of culturing the host cell of claim 21.

agf
#2